国际医药卫生导报
國際醫藥衛生導報
국제의약위생도보
INTERNATIONAL MEDICINE & HEALTH GUIDANCE NEWS
2010年
2期
196-199
,共4页
恩替卡韦%HBeAg阳性%慢性乙型肝炎%重度
恩替卡韋%HBeAg暘性%慢性乙型肝炎%重度
은체잡위%HBeAg양성%만성을형간염%중도
Entecavir%HBeAg-positive%Chronic hepatitis B%Severe-degree
目的 评估恩替卡韦治疗HBeAg阳性慢性重度乙型肝炎临床疗效.方法 将HBeAg阳性慢性重度乙型肝炎患者58例随机分为治疗组29例和对照组29例,治疗组用恩替卡韦0.5 mg/天治疗,疗程为48周,前4周加用保肝药物治疗.对照组患者保肝治疗,疗程为48周.结果 治疗组ALT复常率(93.1%)、HBeAg阴转率(44.8%)、HBeAg/抗HBe转换率(41.4%)、HBV DNA阴转率93.1%均显著高于对照组(P值<0.05),且治疗组肝组织病理炎症活动度好转率(93.1%)和纤维化好转率(72.4%)也显著高于对照组(P值<0.05),对照组有13.8%发生重型肝炎和13.8%发生肝硬化,而治疗组无病人发生重型肝炎和肝硬化(P值<0.05).结论 恩替卡韦对HBeAg阳性慢性重度乙型肝炎有较好的临床疗效,能阻止重型肝炎和肝硬化的发生.
目的 評估恩替卡韋治療HBeAg暘性慢性重度乙型肝炎臨床療效.方法 將HBeAg暘性慢性重度乙型肝炎患者58例隨機分為治療組29例和對照組29例,治療組用恩替卡韋0.5 mg/天治療,療程為48週,前4週加用保肝藥物治療.對照組患者保肝治療,療程為48週.結果 治療組ALT複常率(93.1%)、HBeAg陰轉率(44.8%)、HBeAg/抗HBe轉換率(41.4%)、HBV DNA陰轉率93.1%均顯著高于對照組(P值<0.05),且治療組肝組織病理炎癥活動度好轉率(93.1%)和纖維化好轉率(72.4%)也顯著高于對照組(P值<0.05),對照組有13.8%髮生重型肝炎和13.8%髮生肝硬化,而治療組無病人髮生重型肝炎和肝硬化(P值<0.05).結論 恩替卡韋對HBeAg暘性慢性重度乙型肝炎有較好的臨床療效,能阻止重型肝炎和肝硬化的髮生.
목적 평고은체잡위치료HBeAg양성만성중도을형간염림상료효.방법 장HBeAg양성만성중도을형간염환자58례수궤분위치료조29례화대조조29례,치료조용은체잡위0.5 mg/천치료,료정위48주,전4주가용보간약물치료.대조조환자보간치료,료정위48주.결과 치료조ALT복상솔(93.1%)、HBeAg음전솔(44.8%)、HBeAg/항HBe전환솔(41.4%)、HBV DNA음전솔93.1%균현저고우대조조(P치<0.05),차치료조간조직병리염증활동도호전솔(93.1%)화섬유화호전솔(72.4%)야현저고우대조조(P치<0.05),대조조유13.8%발생중형간염화13.8%발생간경화,이치료조무병인발생중형간염화간경화(P치<0.05).결론 은체잡위대HBeAg양성만성중도을형간염유교호적림상료효,능조지중형간염화간경화적발생.
Objective To evaluate the effects of Entecavir for patients of chronic severe-degree hepatitis B with HBeAg-positive.Methods 58 patients with chronic severe-degree hepatitis B were randomly divided into two groups (treatment group and control group ).29 patients in the treatment group were treated with Entecavir 0.5mg/d for 48 weeks and protect-liver drug for the first 4 weeks.29 patients in control group were treated with protect-liver drug for 48 weeks.Results After therapy for 48 weeks, ALT normalization-rate, the negative-rate of serum HBV DNA and HBeAg, the transition-rate of serum HBeAg/ Anti-Hbe in the treated group were all significantly higher than that of the control group( 93.1%vs593%, 93.1%vs11.1%, 44.8%vs11.1%, 41.4%vs11.1%, respectively,χ2-value were 8.98, 37.79, 7.79,6.53. P< 0.005, <0.001, <0.01, <0.05, respectively ).The improve-rate of hepatic histological activity and hepatic fibrosis in needle liver biopsy specimens in the treatment group were all significantly higher than that in the control group ( 93.1 %vs44.4%, 72.4%vs33.3%, respectively, x2-value were 15.66, 8.58, P <0.001, <0.005, respectively ).Conclusion The clinical efficacy of entecavir were better than protect-liver drug in patients of chronic severe-degree hepatitis B with HBeAg-positive.Entecavir can prevent severe hepatitis and hepatocirrhosis in these patients.
